Orbital fat volume in the inferolateral quadrant in Japanese: a guide for orbital fat decompression without injury to the oculomotor nerve

2017 ◽  
Vol 38 (6) ◽  
pp. 2471-2475 ◽  
Author(s):  
Yasuhiro Takahashi ◽  
Yoshiyuki Kitaguchi ◽  
Maria Suzanne Sabundayo ◽  
Hirohiko Kakizaki
Keyword(s):  
Oculomotor Nerve ◽  
Orbital Fat ◽  
Fat Volume

Orbital fat expansion in thyroid eye disease is related to age

2019 ◽  
Vol 30 (5) ◽  
pp. 1004-1007 ◽  
Author(s):  
Shoaib Ugradar ◽  
Daniel B Rootman
Keyword(s):  
Standard Deviation ◽  
Muscle Volume ◽  
Thyroid Eye Disease ◽  
Secondary Outcome ◽  
Eye Disease ◽  
Decompression Surgery ◽  
Analysis Tool ◽  
Orbital Fat ◽  
Orbital Volume ◽  
Fat Volume

Purpose: To objectively measure the differential expansion of orbital fat and muscle volume in patients with thyroid eye disease. Methods: In this retrospective study, eligible participants were adults with clinical evidence of thyroid eye disease and high-resolution computed tomography scans of their orbits. Patients with a history of decompression surgery and/or medical or other conditions that could alter the orbital anatomy were excluded. Three dimensional reconstructions of the orbits allowed the calculation of the fat volume, muscle volume and bony orbital volume using the MIMICS imaging analysis tool. Both orbits from each patient were included without bias through the use of the generalized estimating equation. The primary outcome was the measurement of fat volume. Secondary outcome measures included the correlation of the muscle volume, bony orbital volume and exophthalmometry with age. Results: Fifty patients with thyroid eye disease who were included contributed 100 orbits. The sample included 29 females (age 57, standard deviation = 14.8) and 21 males (age 52, standard deviation = 18.14). Mean (standard deviation) exophthalmometry measurement was 21.58 (4.01). Fat volume and exophthalmometry were negatively correlated with age (p = 0.00001 and p = 0.00001, respectively). Muscle volume (p = 0.985) and bony orbital volume (p = 0.484) did not correlate with age. Conclusion: Older patients with thyroid eye disease have less expansion of fat volume compared with younger patients. There are no associations between age and the bony orbital volume or muscle volume. These results support the growing body of evidence which suggests that the pathophysiology of TED is different in older patient.

scholarly journals Orbital Fat Volume After Treatment with Topical Prostaglandin Agonists

2020 ◽  
Vol 61 (5) ◽  
pp. 46
Author(s):  
Jessica Y. Chen ◽  
Alan Le ◽  
Joseph Caprioli ◽  
JoAnn A. Giaconi ◽  
Kouros Nouri-Mahdavi ◽  
...  
Keyword(s):  
Orbital Fat ◽  
Fat Volume

Measurement of Eyelid and Orbital Fat Volume in Different Age Groups by Computed Tomography

2010 ◽  
Vol 30 (3) ◽  
pp. 995-1001 ◽  
Author(s):  
Yonca ÖZKAN ARAT ◽  
Christof KARMONIK ◽  
Imtiaz A A CHAUDHRY ◽  
Anıl ARAT ◽  
Serhat TOTAN ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Age Groups ◽  
Orbital Fat ◽  
Fat Volume

scholarly journals Orbital Volumetry in Graves' Orbitopathy: Muscle and Fat Involvement in relation to Dysthyroid Optic Neuropathy

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Moug Al-Bakri ◽  
Åse Krogh Rasmussen ◽  
Carsten Thomsen ◽  
Peter Bjerre Toft
Keyword(s):  
Optic Nerve ◽  
Optic Neuropathy ◽  
Ct Scans ◽  
Orbital Decompression ◽  
Orbital Fractures ◽  
Relative Significance ◽  
Dysthyroid Optic Neuropathy ◽  
Orbital Fat ◽  
Graves Orbitopathy ◽  
Fat Volume

Purpose. We wanted to investigate the relative significance of fat and muscle enlargement in the development of dysthyroid optic neuropathy (DON) in Graves’ orbitopathy (GO). Methods. Preoperative coronal CT scans of 13 patients with and without DON who subsequently underwent orbital decompression were retrospectively analyzed. Thirteen patients imaged for unilateral orbital fractures served as controls. Results. The retrobulbar muscle volume was 2.1 ± 0.5 cm3 (mean ± SD) in controls, 4.3 ± 1.5 cm3 in GO without DON, and 4.7 ± 1.7 cm3 in GO with DON. The retrobulbar fat volume was 5.4 ± 1.6 cm3 in controls, 8.7 ± 8.0 cm3 in GO without DON, and 9.4 ± 3.1 cm3 in GO with DON. The muscle and fat volumes were higher in patients with GO than in controls (P<0.001), but the volumes in orbits with and without DON were not significantly different. The volume of the optic nerve were similar in the 3 groups. The number of apical, coronal 2 mm thick slices with no fat was 2.9 ± 0.9 in normal orbits, it was 4.1 ± 1.0 in GO orbits without DON and 5.3 ± 0.8 in GO orbits with DON (P=0.007). Conclusion. Apical muscle enlargement may be more important than orbital fat enlargement in the development of DON. However, the fact that apical crowding and muscle enlargement also occur in orbits without DON suggests that other factors also play a role in the development of DON.

MRI diagnosis of orbital fat volume in patients with Graves orbithopathy

2020 ◽  
pp. 148-149
Author(s):  
O.P. Sadovskaya ◽  
◽  
L.V. Dravitsa ◽  
H.A. Alhaj ◽  
◽  
...  
Keyword(s):  
Orbital Fat ◽  
Mri Diagnosis ◽  
Fat Volume

scholarly journals Thyroid-associated Orbitopathy: Quantitative Evaluation of the Orbital Fat Volume and Edema Using IDEAL-FSE

2019 ◽  
Vol 6 ◽  
pp. 182-186 ◽  
Author(s):  
Yoko Kaichi ◽  
Keizo Tanitame ◽  
Hiroaki Terada ◽  
Hideki Itakura ◽  
Haruya Ohno ◽  
...  
Keyword(s):  
Quantitative Evaluation ◽  
Orbital Fat ◽  
Fat Volume

Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease

2020 ◽  
pp. bjophthalmol-2020-317806
Author(s):  
Amy Patel Jain ◽  
Norman Gellada ◽  
Shoaib Ugradar ◽  
Ada Kumar ◽  
George Kahaly ◽  
...  
Keyword(s):  
Human Monoclonal Antibody ◽  
Clinical Manifestations ◽  
Post Treatment ◽  
Thyroid Eye Disease ◽  
Phase Iii ◽  
Eye Disease ◽  
Control Group ◽  
Orbital Fat ◽  
Orbital Imaging ◽  
Fat Volume

PurposeThyroid eye disease (TED) is a progressive, debilitating and potentially vision-threatening autoimmune disease. Teprotumumab, a novel human monoclonal antibody, has been shown to reverse the clinical manifestations of TED. Patients receiving teprotumumab have been shown in two multicenter, randomized placebo-controlled trials to have decreased proptosis, diplopia and inflammation after 24 weeks of treatment. This study aims to analyse volumetric and inflammatory changes on orbital imaging prior to and after teprotumumab treatment from one of these trials.DesignRetrospective review.SubjectsSix patients enrolled in the phase III teprotumumab clinical trial (OPTIC, NCT03298867) with active TED who received 24 weeks of teprotumumab and had pre- and post-treatment orbital imaging (CT or MRI). Additionally, 12 non-TED patients (24 orbits) were analysed as a comparative control group.Methods3D volumetric calculations of the extraocular muscles (EOMs), orbital fat, and bony orbit were measured using previously validated image processing software. 3D volumetric results and changes in EOM inflammation were compared with clinical measurements of TED.ResultsTotal EOM volume within each orbit was markedly reduced post-teprotumumab in all patients (n=six patients, 12/12 orbits, p<0.02). There was no statistical difference in post-treatment EOM volume when compared to non-TED controls. Total orbital fat volume was also reduced in 11 of 12 studied orbits (n=six patients, p=0.04). Overall EOM inflammation based on MRI signal intensity ratio was reduced in 8/8 orbits (n=four patients, p<0.01).ConclusionOrbital imaging demonstrated decreased EOM volumes and orbital fat tissue volumes after teprotumumab treatment.

Sign in / Sign up

Export Citation Format

Share Document